10 hours ago
ASCO 2025: Key Highlights in Advanced Lung Cancer
Just returned from ASCO 2025, Isabel Preeshagul, DO, comments on intriguing data that were presented, including results from REZILIENT1, which showed a 35% response rate for zipalertinib in patients with epidermal growth factor receptor exon 20-altered stage IV non-small cell lung cancer (NSCLC), even those previously treated with targeted therapies, with manageable toxicity. An unexpected finding from another study in the advanced NSCLC space suggested that administering immunochemotherapy before 3:00 PM was associated with better outcomes, possibly due to circadian influences on immune response.
In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and exertional shortness of breath. Finally, Dr Preeshagul notes how the IMforte study reported promising results for maintenance atezolizumab plus lurbinectedin, with improved progression-free survival and overall survival, making it a potential option pending further risk-benefit discussion.
